Keros Therapeutics (KROS) Change in Account Payables (2019 - 2025)
Keros Therapeutics posted quarterly Change in Account Payables of -$697000.0 for Q4 2025, down 137.88% year-on-year from $1.8 million in Q4 2024, and up 76.41% on a QoQ basis from -$3.0 million in Q3 2025.
Keros Therapeutics (KROS) has 7 years of Change in Account Payables data on file, last reported at -$697000.0 in Q4 2025.
- For the quarter ending Q4 2025, Change in Account Payables fell 137.88% year-over-year to -$697000.0; the trailing twelve-month figure through Dec 2025 stood at -$3.0 million (down 1105.22% YoY), and the FY2025 full-year result was -$3.0 million, down 1105.22% from the prior year.
- Change in Account Payables for Q4 2025 stood at -$697000.0, up from -$3.0 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $4.7 million in Q2 2022 and bottomed at -$5.0 million in Q3 2022.
- The 5-year median for Change in Account Payables is -$79500.0 (2023), against an average of -$27950.0.
- The widest annual swing landed in 2024, when Change in Account Payables tumbled 774.73%; it then jumped 8678.26% in 2025.
- A 5-year view of Change in Account Payables shows it stood at $823000.0 in 2021, then decreased by 27.7% to $595000.0 in 2022, then surged by 75.46% to $1.0 million in 2023, then tumbled by 128.07% to -$293000.0 in 2024, then slumped by 137.88% to -$697000.0 in 2025.
- The last three Change in Account Payables figures came in at -$697000.0 (Q4 2025), -$3.0 million (Q3 2025), and -$1.4 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -3.26 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 35.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Keros Therapeutics | 403.85 Mn | 116.45 Mn | - | -697,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -697,000.00 |
| Dec 31, 2025 | -697,000.00 |
| Sep 30, 2025 | -2.96 Mn |
| Sep 30, 2025 | -2.96 Mn |
| Jun 30, 2025 | -1.37 Mn |
| Jun 30, 2025 | -1.37 Mn |
| Mar 31, 2025 | 2.02 Mn |
| Mar 31, 2025 | 2.02 Mn |
| Dec 31, 2024 | -293,000.00 |
| Dec 31, 2024 | -293,000.00 |
| Sep 30, 2024 | -1.59 Mn |
| Sep 30, 2024 | -1.59 Mn |
| Jun 30, 2024 | 1.61 Mn |
| Jun 30, 2024 | 1.61 Mn |
| Mar 31, 2024 | 23,000.00 |
| Mar 31, 2024 | 23,000.00 |
| Dec 31, 2023 | 1.04 Mn |
| Dec 31, 2023 | 1.04 Mn |
| Sep 30, 2023 | -182,000.00 |
| Sep 30, 2023 | -182,000.00 |
| Jun 30, 2023 | -570,000.00 |
| Jun 30, 2023 | -570,000.00 |
| Mar 31, 2023 | 1.32 Mn |
| Mar 31, 2023 | 1.32 Mn |
| Dec 31, 2022 | 595,000.00 |
| Dec 31, 2022 | 595,000.00 |
| Sep 30, 2022 | -4.99 Mn |
| Sep 30, 2022 | -4.99 Mn |
| Jun 30, 2022 | 4.66 Mn |
| Jun 30, 2022 | 4.66 Mn |
| Mar 31, 2022 | -668,000.00 |
| Mar 31, 2022 | -668,000.00 |
| Dec 31, 2021 | 823,000.00 |
| Dec 31, 2021 | 823,000.00 |
| Sep 30, 2021 | 1.44 Mn |
| Sep 30, 2021 | 1.44 Mn |
| Jun 30, 2021 | -1.64 Mn |
| Jun 30, 2021 | -1.64 Mn |
| Mar 31, 2021 | 859,000.00 |
| Mar 31, 2021 | 859,000.00 |
| Dec 31, 2020 | 433,000.00 |
| Dec 31, 2020 | 433,000.00 |
| Sep 30, 2020 | -3.14 Mn |
| Sep 30, 2020 | -3.14 Mn |
| Jun 30, 2020 | 2.96 Mn |
| Jun 30, 2020 | 2.96 Mn |
| Mar 31, 2020 | -193,000.00 |
| Mar 31, 2020 | -193,000.00 |
| Dec 31, 2019 | -130,000.00 |
| Dec 31, 2019 | -130,000.00 |
| Sep 30, 2019 | 846,000.00 |
| Sep 30, 2019 | 846,000.00 |
| Jun 30, 2019 | -217,000.00 |
| Jun 30, 2019 | -217,000.00 |
| Mar 31, 2019 | 813,000.00 |
| Mar 31, 2019 | 813,000.00 |